These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19451287)

  • 1. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
    Rodvold KA; Nicolau DP; Lodise TP; Khashab M; Noel GJ; Kahn JB; Gotfried M; Murray SA; Nicholson S; Laohavaleeson S; Tessier PR; Drusano GL
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3294-301. PubMed ID: 19451287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
    Laohavaleeson S; Tessier PR; Nicolau DP
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2389-94. PubMed ID: 18411322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of vancomycin into epithelial lining fluid in healthy volunteers.
    Lodise TP; Drusano GL; Butterfield JM; Scoville J; Gotfried M; Rodvold KA
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5507-11. PubMed ID: 21911567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.
    Bhalodi AA; Crandon JL; Biek D; Nicolau DP
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6160-5. PubMed ID: 22985880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
    Louie A; Fregeau C; Liu W; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3325-30. PubMed ID: 19364849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
    Craig WA; Andes DR
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3492-6. PubMed ID: 18676887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation.
    Lodise TP; Gotfried M; Barriere S; Drusano GL
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2300-4. PubMed ID: 18426898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia.
    Harigaya Y; Bulitta JB; Forrest A; Sakoulas G; Lesse AJ; Mylotte JM; Tsuji BT
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3894-901. PubMed ID: 19596879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is One Sample Enough? β-Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model.
    Motos A; Kuti JL; Li Bassi G; Torres A; Nicolau DP
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.
    Lodise TP; Kinzig-Schippers M; Drusano GL; Loos U; Vogel F; Bulitta J; Hinder M; Sörgel F
    Antimicrob Agents Chemother; 2008 Jun; 52(6):1945-51. PubMed ID: 17485507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
    Xiao AJ; Miller BW; Huntington JA; Nicolau DP
    J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation study.
    Muller AE; Schmitt-Hoffmann AH; Punt N; Mouton JW
    Antimicrob Agents Chemother; 2013 May; 57(5):2047-53. PubMed ID: 23403430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
    Barbour A; Schmidt S; Sabarinath SN; Grant M; Seubert C; Skee D; Murthy B; Derendorf H
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2773-6. PubMed ID: 19364847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
    Lepak AJ; Zhao M; Andes DR
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.
    Fernandez J; Hilliard JJ; Abbanat D; Zhang W; Melton JL; Santoro CM; Flamm RK; Bush K
    Antimicrob Agents Chemother; 2010 Jan; 54(1):116-25. PubMed ID: 19884364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.
    Riccobene TA; Pushkin R; Jandourek A; Knebel W; Khariton T
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5849-57. PubMed ID: 27431215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
    Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
    Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.